DE69833509T2 - Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation - Google Patents
Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation Download PDFInfo
- Publication number
- DE69833509T2 DE69833509T2 DE69833509T DE69833509T DE69833509T2 DE 69833509 T2 DE69833509 T2 DE 69833509T2 DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T DE69833509 T DE 69833509T DE 69833509 T2 DE69833509 T2 DE 69833509T2
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- oder
- aryl
- und
- ist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C1C=C*=C*1 Chemical compound C1C=C*=C*1 0.000 description 18
- IKGHIFGXPVLPFD-NSHDSACASA-N CC(N[C@@H](Cc1ccccc1)C(OC)=O)=O Chemical compound CC(N[C@@H](Cc1ccccc1)C(OC)=O)=O IKGHIFGXPVLPFD-NSHDSACASA-N 0.000 description 3
- HIDNBRRMSIYCEM-UHFFFAOYSA-N CC(C(CN)S)=O Chemical compound CC(C(CN)S)=O HIDNBRRMSIYCEM-UHFFFAOYSA-N 0.000 description 1
- PMSSGBHWXUPKOP-UHFFFAOYSA-N CC(C(CS)N)=O Chemical compound CC(C(CS)N)=O PMSSGBHWXUPKOP-UHFFFAOYSA-N 0.000 description 1
- MBHINSULENHCMF-UHFFFAOYSA-N CCC(N(C)C)=O Chemical compound CCC(N(C)C)=O MBHINSULENHCMF-UHFFFAOYSA-N 0.000 description 1
- ZXLYYQUMYFHCLQ-UHFFFAOYSA-N CN(C(c1c2cccc1)=O)C2=O Chemical compound CN(C(c1c2cccc1)=O)C2=O ZXLYYQUMYFHCLQ-UHFFFAOYSA-N 0.000 description 1
- DDIIAJRLFATEEE-UHFFFAOYSA-N CN(C(c1c2cccc1)=O)S2(=O)=O Chemical compound CN(C(c1c2cccc1)=O)S2(=O)=O DDIIAJRLFATEEE-UHFFFAOYSA-N 0.000 description 1
- ULZCOWMSBOJCLT-UHFFFAOYSA-N CN(CC1)CCS1(=O)=O Chemical compound CN(CC1)CCS1(=O)=O ULZCOWMSBOJCLT-UHFFFAOYSA-N 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N CN(CCC1)C1=O Chemical compound CN(CCC1)C1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 1
- PJAAXNHOFKYZPR-MUUNZHRXSA-N C[C@@](C(CC1)CCN1C(CC(CC1)CCN1C(N)=O)=O)(c(c(CC1)cc(Cl)c2)c2Br)C(NC2)=C1C=C2Br Chemical compound C[C@@](C(CC1)CCN1C(CC(CC1)CCN1C(N)=O)=O)(c(c(CC1)cc(Cl)c2)c2Br)C(NC2)=C1C=C2Br PJAAXNHOFKYZPR-MUUNZHRXSA-N 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N c1ccc2ncccc2c1 Chemical compound c1ccc2ncccc2c1 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99602797A | 1997-12-22 | 1997-12-22 | |
| US14352998A | 1998-08-28 | 1998-08-28 | |
| US143529 | 1998-08-28 | ||
| US18196998A | 1998-10-29 | 1998-10-29 | |
| US181969 | 1998-10-29 | ||
| PCT/US1998/026224 WO1999032114A1 (en) | 1997-12-22 | 1998-12-21 | Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases |
| US996027 | 2004-11-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69833509D1 DE69833509D1 (de) | 2006-04-20 |
| DE69833509T2 true DE69833509T2 (de) | 2006-10-26 |
Family
ID=27385940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69833509T Expired - Lifetime DE69833509T2 (de) | 1997-12-22 | 1998-12-21 | Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1041985B1 (enExample) |
| JP (1) | JP4502503B2 (enExample) |
| KR (1) | KR100700907B1 (enExample) |
| CN (1) | CN1129431C (enExample) |
| AR (1) | AR017440A1 (enExample) |
| AT (1) | ATE317697T1 (enExample) |
| AU (1) | AU756762B2 (enExample) |
| BR (1) | BR9814419A (enExample) |
| CA (1) | CA2315693C (enExample) |
| CL (1) | CL2007001889A1 (enExample) |
| CO (1) | CO5080764A1 (enExample) |
| CZ (1) | CZ298511B6 (enExample) |
| DE (1) | DE69833509T2 (enExample) |
| DK (1) | DK1041985T3 (enExample) |
| ES (1) | ES2255196T3 (enExample) |
| HU (1) | HUP0102473A3 (enExample) |
| IL (1) | IL136462A0 (enExample) |
| MY (1) | MY137303A (enExample) |
| NO (1) | NO326832B1 (enExample) |
| NZ (1) | NZ504928A (enExample) |
| PE (1) | PE20000042A1 (enExample) |
| PT (1) | PT1041985E (enExample) |
| SK (1) | SK285584B6 (enExample) |
| TW (1) | TW581763B (enExample) |
| WO (1) | WO1999032114A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2787327B1 (fr) * | 1998-12-21 | 2003-01-17 | Aventis Pharma Sa | Compositions contenant des inhibiteurs de farnesyle transferase |
| DE60016625T2 (de) * | 1999-11-09 | 2005-12-22 | Societe De Conseils De Recherches Et D'applications Scientifiques(S.C.R.A.S.) | Zusammensetzung enthaltend einen inhibitor der signaltransduktion von heterotrimerischen g-proteinen in kombination mit einem anderen anti-krebs-mittel zu einer therapeutischen verwendung in der krebsbehandlung |
| AU2292801A (en) * | 1999-12-22 | 2001-07-03 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Compositions and methods for treatment of breast cancer |
| US20030186925A1 (en) * | 2000-02-29 | 2003-10-02 | Palmer Peter Albert | Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives |
| EP1261348A2 (en) * | 2000-02-29 | 2002-12-04 | Janssen Pharmaceutica N.V. | Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents |
| WO2001064197A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives |
| WO2001064226A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with platinum compounds |
| WO2001064196A2 (en) * | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with vinca alkaloids |
| EP1267871A2 (en) * | 2000-02-29 | 2003-01-02 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives |
| TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| US6645966B2 (en) * | 2001-01-22 | 2003-11-11 | Schering Corporation | Treatment of malaria with farnesyl protein transferase inhibitors |
| JP4969016B2 (ja) * | 2001-02-15 | 2012-07-04 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗エストロゲン剤とファルネシルプロテイントランスフェラーゼ阻害剤の組み合わせ物 |
| HUP0402401A2 (hu) * | 2001-11-30 | 2005-03-29 | Schering Corp. | Rák kezelésére szolgáló eljárások egy FPT inhibitor és daganatellenes szerek felhasználásával |
| EP1453513A1 (en) * | 2001-12-03 | 2004-09-08 | Schering Corporation | Use of fpt inhibitors and at least two antineoplastic agents in the treatment of cancer |
| WO2008022535A1 (fr) * | 2006-08-09 | 2008-02-28 | Tian Jin Tasly Group Co., Ltd. | Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique |
| CN105198758A (zh) * | 2015-09-22 | 2015-12-30 | 湖南大学 | 一种高纯度(z)-他莫昔酚的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047246A (en) * | 1988-09-09 | 1991-09-10 | Bristol-Myers Company | Direct compression cyclophosphamide tablet |
| AU665341B2 (en) * | 1990-12-18 | 1996-01-04 | Wellcome Foundation Limited, The | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| JP2767176B2 (ja) * | 1992-12-15 | 1998-06-18 | 大塚製薬株式会社 | 抗癌剤 |
| US5637688A (en) * | 1994-12-13 | 1997-06-10 | Eli Lilly And Company | Process for preparing 1-(2'-deoxy-2'-difluoro-d-ribofuranosyl)-4-aminopyrimidin-2-one hydrochloride |
| DE69635114T2 (de) * | 1995-08-09 | 2006-03-02 | Banyu Pharmaceutical Co., Ltd. | Proteinfarnesyltransferase-inhibitoren in kombination mit hmgcoa-reduktase-inhibitoren zur behandlung von aids |
| TW350844B (en) * | 1995-12-22 | 1999-01-21 | Schering Corp | Tricyclic amides useful to inhibition of G-protein function and for treatment of proliferative diseases |
| EP0932399B1 (en) * | 1996-03-12 | 2006-01-04 | PG-TXL Company, L.P. | Water soluble paclitaxel prodrugs |
| JP2000507584A (ja) * | 1996-04-03 | 2000-06-20 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| US20020034725A1 (en) * | 1996-04-15 | 2002-03-21 | W. Gillies Mckenna | Sensitization of cells to radiation and and chemotherapy |
| CA2251955A1 (en) * | 1996-04-18 | 1997-10-23 | Nancy E. Kohl | A method of treating cancer |
| JP2000508335A (ja) * | 1996-05-30 | 2000-07-04 | メルク エンド カンパニー インコーポレーテッド | 癌の治療方法 |
| US6337992B1 (en) * | 1997-01-29 | 2002-01-08 | Philips Medical Systems Technologies Ltd. | Predictive bolus tracking |
| CA2282683A1 (en) * | 1997-02-18 | 1998-08-20 | Canji, Inc. | Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
-
1998
- 1998-12-21 CZ CZ20002236A patent/CZ298511B6/cs not_active IP Right Cessation
- 1998-12-21 NZ NZ504928A patent/NZ504928A/xx unknown
- 1998-12-21 CA CA2315693A patent/CA2315693C/en not_active Expired - Fee Related
- 1998-12-21 PT PT98963829T patent/PT1041985E/pt unknown
- 1998-12-21 AT AT98963829T patent/ATE317697T1/de not_active IP Right Cessation
- 1998-12-21 IL IL13646298A patent/IL136462A0/xx unknown
- 1998-12-21 HU HU0102473A patent/HUP0102473A3/hu unknown
- 1998-12-21 CO CO98075842A patent/CO5080764A1/es unknown
- 1998-12-21 EP EP98963829A patent/EP1041985B1/en not_active Expired - Lifetime
- 1998-12-21 KR KR1020007006938A patent/KR100700907B1/ko not_active Expired - Fee Related
- 1998-12-21 WO PCT/US1998/026224 patent/WO1999032114A1/en not_active Ceased
- 1998-12-21 AR ARP980106565A patent/AR017440A1/es unknown
- 1998-12-21 MY MYPI98005809A patent/MY137303A/en unknown
- 1998-12-21 DK DK98963829T patent/DK1041985T3/da active
- 1998-12-21 AU AU19072/99A patent/AU756762B2/en not_active Ceased
- 1998-12-21 ES ES98963829T patent/ES2255196T3/es not_active Expired - Lifetime
- 1998-12-21 PE PE1998001263A patent/PE20000042A1/es not_active Application Discontinuation
- 1998-12-21 JP JP2000525105A patent/JP4502503B2/ja not_active Expired - Fee Related
- 1998-12-21 BR BR9814419-7A patent/BR9814419A/pt not_active Application Discontinuation
- 1998-12-21 CN CN98813742A patent/CN1129431C/zh not_active Expired - Fee Related
- 1998-12-21 SK SK898-2000A patent/SK285584B6/sk not_active IP Right Cessation
- 1998-12-21 DE DE69833509T patent/DE69833509T2/de not_active Expired - Lifetime
- 1998-12-21 TW TW087121355A patent/TW581763B/zh not_active IP Right Cessation
-
2000
- 2000-06-21 NO NO20003229A patent/NO326832B1/no not_active IP Right Cessation
-
2007
- 2007-06-27 CL CL2007001889A patent/CL2007001889A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60032226T2 (de) | Verfahren zur induktion von krebszellentod und tumorregression | |
| DE69833509T2 (de) | Benzocycloheptapyridinezusammensetzungen und antineoplastische arzneimittel als kombinationstherapeutika für therapie der zellproliferation | |
| US6333333B1 (en) | Methods for treating proliferative diseases | |
| DE69625518T2 (de) | Wirkstoff zur behandlung neurodegenerativer störungen | |
| DE19542281C2 (de) | Verwendung von Epinastin für die Behandlung der Migräne | |
| DE19814838C2 (de) | Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung | |
| DE69535234T2 (de) | Mittel zur behandlung der allergischen rhinitis und anderer erkrankungen enthaltend descarboethoxyloratadin | |
| DE60130017T2 (de) | Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität | |
| DE69017302T2 (de) | Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten. | |
| DE60214846T2 (de) | Verwendung von mGLuR5 antagonists zur Herstellung von Medikamenten zur Behandlung von empfindlichen X Syndrome, Autismus und geistiger Zurückgebliebenheit | |
| DE69628645T2 (de) | Benzimidazolderivaten-enthaltende pharmazeutische zusammensetzungen zur inhibierung des krebswachstums | |
| WO2002020521A1 (de) | Verwendung von indolderivaten zur behandlung von erkrankungen des zentralen nervensystems | |
| DE68923151T2 (de) | Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen. | |
| DE19953414A1 (de) | Imidazopyridinderivate als Phospodiesterase VII-Hemmer | |
| DE69531722T2 (de) | Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten | |
| DE69623555T2 (de) | Inhibitor der krebsmetastasierung | |
| EP0859613B1 (de) | Verwendung von flupirtin zur prophylaxe und therapie von erkrankungen, die mit einer beeinträchtigung des hämatopoetischen zellsystems einhergehen | |
| DE3873210T2 (de) | Verwendung von benzylpyridin-derivaten zur herstellung eines arzneimittels zur behandlung der demenz. | |
| DE602004011781T2 (de) | Pharmazeutische zubereitungen enthaltend azd 2171 und zd 6126 und verwendungen | |
| DE69919789T2 (de) | Loratadin zur Verwendung als Antiarrhythmikum | |
| DE60318561T2 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
| DE60110628T2 (de) | Antiphlogistische mittel | |
| DE2401446A1 (de) | Pharmazeutische zubereitungen zur linderung von hautproliferationserkrankungen | |
| DE3930282A1 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
| DE69424779T2 (de) | Verwendung von triazinverbindungen bei angstzuständen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |